<DOC>
	<DOCNO>NCT00193973</DOCNO>
	<brief_summary>Idarubicin combine high dose methotrexate moderate dose radiotherapy achieve similar survival outcome reduce neurotoxicity compare regimen use methotrexate high dose radiotherapy .</brief_summary>
	<brief_title>Idarubicin Based Combined Modality Therapy Primary CNS Lymphoma</brief_title>
	<detailed_description>Combined modality therapy PCNSL improve survival outcome cost unacceptable rate neurotoxicity high dose radiotherapy use . Idarubicin activity systemic lymphoma cross blood brain barrier may add efficacy methotrexate . By combine 2 drug moderate dose radiotherapy survival outcome optimal low rate neurotoxicity . Comparison : TROG previously perform phase 2 study use methotrexate high dose radiotherapy allow comparison survival neurotoxicity rate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically proven primary CNS lymphoma . Absence disease outside CNS . ECOG performance status 03 Negative HIV status . Peripheral blood count granulocytes &gt; 1.5 x 109L platelet &gt; 100 x 109L . Serum creatinine &lt; 150mmol/L . Serum bilirubin &lt; 1.5 time AST &lt; 2 time upper limit normal . Age &gt; 18 &lt; =70 year . Patients must give write informed consent . Corticosteroids prior histological diagnosis allow . Previous history malignancy ( nonmelanomatous skin carcinoma , carcinoma situ cervix completely excise ) . Patients pregnant lactate . NYHA ( New York State Heart Association classification ) cardiac failure grade 3 Macroscopic spinal thecal spinal cord disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>PCNSL</keyword>
	<keyword>Primary CNS lymphoma</keyword>
</DOC>